By
Trending Posts
AI-Powered Insilico Medicine Doses First Patient in Phase…
Cambridge, Mass. — Jan 22, 2025 Insilico Medicine, a biotechnology company leveraging generative artificial intelligence (AI) for drug…
Insilico Medicine’s AI Platform Unveils GBP2 and HCK…
InSilico Medicine — Jan 15, 2025AI-Driven Research Unveils New Therapeutic Approaches Researchers have leveraged artificial intelligence to discover…
Can Yseop and Novartis Cut Drug Development Timelines…
Elite AI Partnership with NovartisYseop has been named among only seven elite AI partners by Novartis, aiming to…
Dyno Therapeutics Reveals Roche’s Decision to Exercise Option…
January 13, 2025 Dyno Therapeutics has announced that Roche has exercised its option to license a novel AAV…
NVIDIA Joins Forces with Industry Leaders to Revolutionize…
J.P. Morgan Healthcare Conference — Jan 13, 2025 At the J.P. Morgan Healthcare Conference, NVIDIA unveiled transformative partnerships…
Insilico Medicine Identifies Novel Endometriosis Targets and Repurposes…
FLORENCE, Italy & CAMBRIDGE, Mass.— Jan 10, 2025AI-Driven Research Unveils New Therapeutic Approaches Researchers have leveraged artificial intelligence…
XtalPi and UCB Partner to Advance AI-Powered Biologic…
Cambridge, MA – Jan 10 2025 XtalPi Inc. (HKEX: 2228.HK), a leader in AI-powered pharmaceutical technology, announced a…
Can AI-Powered Drug Discovery Redefine Cardiometabolic Treatment? Novo…
Key Takeaways for Industry Leaders A Landmark Expansion: 20 Programs, $4.6 Billion, and a Bold Vision for AI…
Recursion Advances AI-Powered Oncology Pipeline with REC-3565 and…
Salt Lake City – January 7, 2025 Recursion, a clinical-stage TechBio company pioneering the integration of artificial intelligence…
Trending Posts
Latest Stories
How Is Roche’s Expansive 2025 Pipeline and Innovative Alzheimer’s Program Shaping the Future of Biopharma and Diagnostics?
Key Highlights: Broad and Deep Pharmaceutical Pipeline ExpansionSince mid-2023, Roche has significantly enhanced its clinical…
Could Eli Lilly’s $1.3 Billion GPCR Deal with Superluminal Medicines Unlock a New Era in Targeted Therapeutics?
Key Highlights Eli Lilly Taps AI-Powered Drug Discovery in Landmark GPCR Agreement Eli Lilly has…
How Will Bayer’s $1.3 Billion Bet on KRAS G12D and Novartis’ Triple Phase 3 Wins Transform Cancer and Immune Therapy?
Key Highlights Bayer Targets KRAS G12D Mutation with Landmark Licensing Deal Bayer has entered a…
Can GSK’s Gepotidacin Priority FDA Review and Strategic Acquisitions Accelerate Its Antibiotic and Specialty Medicine Leadership in 2025?
Key Highlights: FDA Priority Review of Gepotidacin for GonorrhoeaGSK submitted a supplemental New Drug Application…
Gallery
